By Kathleen Gallagher , a Madison company focused on diagnosis and individualized treatment of neurological disorders, said Wednesday it has received a $2.7 million grant from the that will help fund what the company says is the largest-ever clinical study of the metabolism of children with autism spectrum disorder. Stemina plans to ultimately enroll 1,500 subjects at six sites across the country in an effort to confirm that sets of metabolic molecules can detect subtypes of autism, the company said in a news release. This research has potential to make it possible to use a small blood sample to achieve earlier diagnosis and individualized treatment, the release said. The study is also...
↧